Navigation Links
Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations
Date:11/3/2009

KALAMAZOO, Mich., Nov. 3 /PRNewswire/ -- Tolera Therapeutics, Inc., announced it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) for its lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation. TOL101 is a novel biologic protein that is designed to safely and specifically target T cells, components of the immune system that play a key role in the rejection, and ultimate failure, of transplanted organs. Organ transplantation is often the only viable treatment for many end-stage organ diseases.

"We are extremely pleased with our progress toward bringing TOL101 to the clinic," commented John J. Puisis, President and CEO of Tolera. "This action marks an important development milestone as the company continues its drive to address the patient's need for safer and more effective immune suppression therapy. Current industry practices and pipelines offer limited and incomplete solutions to advance patient care and meet this critical need. Pending acceptance by the FDA, we intend to conduct clinical studies starting in 2010."

Tolera also announced the appointment of Leslie O'Toole to lead its clinical operations as Director, Clinical Programs. O'Toole brings over 20 years of industry experience with 16 years focusing on clinical research management. Mr. Puisis added "We're excited about adding Leslie to our dynamic team. Her depth of clinical research experience adds an important operating aspect to the organization and positions us for continued success." Prior to joining the company, O'Toole was Director, Project Management at Clinimetrics, a full service contract research organization where she was involved in over 35 studies researching drugs in numerous indications with a primary focus in oncology and immunology.

About Tolera Therapeutics: Tolera Therapeutics is a Kalamazoo, Michigan based biotechnology company and
'/>"/>

SOURCE Tolera Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
5. Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on Zero Tolerance for Hepatitis B
6. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
7. Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
10. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
11. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... Chemical Sciences play a significant ... clean air and safe water, healthy food, and ... environmentalists, food scientists, educators, and scientists have a ... field of Chemistry for the national development, and ... of the fastest emerging Sciences, accelerating with a ...
(Date:9/20/2014)... BELLINGHAM, Washington, and PITTSFIELD, Massachusetts, USA (PRWEB) September 20, ... 10 October for the prestigious 2015 Prism Awards ... technology and product inventions from the multi-billion dollar optics ... the international society for optics and photonics , and ... and persistence as well as the versatility of photonics, ...
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary combined ... the specialized Wolvega Horse Clinic. , Due to a ... ruptured 90% and her deep digital flexor tendon 50%. ... for a horse. , The clinic has performed numerous ... This revolutionary regenerative option for ruptured tendons has only ...
Breaking Biology Technology:Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... Life ... Science Companies, ... Trade Zone (FTZ) Service targeting pharmaceutical and,biotechnology companies engaged in ... and creates significant,financial advantages and supply chain efficiencies for life ...
... Nussberger, MD, Today at 9.45am (EST):, "CYT006-AngQb, a Vaccine Against Hypertension ... Reduces Early-Morning and Day-Time Blood Pressure.", The American Heart Association Publishes Today ... ... Safety and Tolerability Profile Confirmed: no, Vaccine-Related Adverse Events Reported ...
... 6 Centocor,Inc., Schering-Plough Corporation, and Mitsubishi ... one million patients have now been,treated with ... therapy worldwide. In fact, REMICADE has been ... other anti-TNF-alpha agents,combined. REMICADE was the first ...
Cached Biology Technology:Sentry Logistic Solutions Launches Foreign Trade Zone Service 2Sentry Logistic Solutions Launches Foreign Trade Zone Service 3Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 2Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 3Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 4Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 5Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 6Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 7REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 2REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 3REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 4REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 5REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 6REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 7REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 8REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 9REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 10REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 11REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 12
(Date:9/18/2014)... how many times it,s demonstrated, it,s still hard ... , But by using a signaling system called ... behavior to suit their population. In short, some ... and act accordingly. , Once the population of ... from innocuous to pathogenic, or from unhelpful to ...
(Date:9/18/2014)... in DNA, tiny strands of nucleic acid that contain ... this genetic data, our DNA is copied into RNA ... perform tasks in our cells. , Several years ... Unlike all other known RNAs, this molecule is circular, ... abundant, little has been known about how they are ...
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... Visualized Experiments) , the revolutionary scientific journal that pairs ... to announce that submissions are now open for ... This new section will enable scientists studying behavior ... video format, bringing this scientific field to new levels ...
... A team of researchers at The New York ... PhD, Director of the NYSCF Laboratory and the NYSCF ... and Michael W. Nestor, PhD, a NYSCF Postdoctoral Research ... of induced pluripotent stem (iPS) cells called embryoid bodies, ...
... Md. (April 1, 2013)Almost four million people die each year ... combustion of biomass fuels (wood, charcoal, crop residues, and dung), ... millions who rely on such products to cook their meals, ... and middle income countries are among the hardest hit by ...
Cached Biology News:NYSCF scientists develop 3-D stem cell culture technique to better understand Alzheimer's disease 2Deadly effects of certain kinds of household air pollution lead to call for biomarker studies 2Deadly effects of certain kinds of household air pollution lead to call for biomarker studies 3
Automated Cell Culture Flask...
Cell Culture Flask, 75 cm, treated polystyrene...
... style shaker flasks have three extra deep ... solutions to improve oxygen or gas transfer ... The long neck reduces splashing and is ... wall thickness provides the proper balance between ...
... IS System is a compact analysis system for ... optics, fluidics, a controller, advanced digital signal processing ... lab analysis system includes the Luminex 100, the ... a DMF file at the FDA, and partner ...
Biology Products: